Market Research Logo

Nuclear Medicine - Global Market Outlook (2015-2022)

Nuclear Medicine - Global Market Outlook (2015-2022)

According to Stratistics MRC, the Global Nuclear Medicine Market is valued at $4.42 billion in 2015 and is expected to grow at a CAGR of 10.55 % to reach $8.92 billion by 2022. Rising demand from emerging nations and the growing incidence of cardiovascular ailments and cancers are some of the key factors driving the market growth. Conversely, strict government regulations and competition from conventional diagnostic methods are hampering the market. Furthermore, technological advancements in neurological applications are anticipated to create ample of opportunities for the market in the future.

North America is the largest market in terms of revenue in 2015 due to several technological advancements within the region. However, Asia Pacific is poised to grow at a faster pace due to the increasing incidence of neurological and cardiovascular diseases and cancer. Various new products are being launched together with the several technological advancements. Thus, new product launch is the key strategy followed by the players to gain the traction in the market.

Some of the key players in global Nuclear Medicine market are Advanced Accelerator Applications S.A., Ashby Gorman Baker Ltd, Bayer Healthcare, Bracco Imaging S.P.A, Cardinal Health, Digirad, Eczcibasi-Monrol Nuclear Products, GE Healthcare, IBA Molecular Imaging, Lantheus Medical Imaging, Mallinckrodt PLC, Mediso Ltd., Nordion, Inc., Philips Healthcare and Siemens Healthcare.

Applications Covered:
Therapeutics
Bone Metastasis
Endocrine Tumors
Lymphoma
Thyroid
Nephrology
Cardiology
Neurology
Other Therapeutic Applications
Diagnostics
Positron emission tomography (PET)
Single Photon Emission Computed Tomography (SPECT)
Types of Nuclear Medicine Covered:
Nuclear Medicine Therapeutic Isotopes
Alpha Emitters
Brachytherapy
Beta Emitters
Nuclear Medicine/Radiopharmaceuticals Diagnostics
Positron emission tomography (PET) Radiopharmaceuticals
Single photon emission tomography (SPECT)
Procedure Volumes Covered
Therapeutic
Alpha Emitters
Beta Emitters
Brachytherapy
Diagnostics
Single photon emission tomography (SPECT) Radiopharmaceuticals
Positron emission tomography (PET) Radiopharmaceuticals
End Users Covered:
Therapeutic
Alpha Emitters
Beta Emitters
Brachytherapy
Diagnostics
Single Photon Emission Computed Tomography (SPECT) Radiopharmaceuticals
Positron Emission Tomography (PET) Radiopharmaceuticals
Stable Isotopes Covered:
Sulphur (S-32)
Oxygen (O-18)
Nitrogen (N-15)
Deuterium (D2)
Carbon (C-13)
Other Stable Isotopes
Regions Covered:
North America
US
Canada
Mexico
Europe
Germany
France
Italy
UK
Spain
Rest of Europe
Asia Pacific
Japan
China
India
Australia
New Zealand
Rest of Asia Pacific
Rest of the World
Middle East
Brazil
Argentina
South Africa
Egypt

What our report offers:
Market share assessments for the regional and country level segments
Market share analysis of the top industry players
Strategic recommendations for the new entrants
Market forecasts for a minimum of 7 years of all the mentioned segments, sub segments and the regional markets
Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
Strategic recommendations in key business segments based on the market estimations
Competitive landscaping mapping the key common trends
Company profiling with detailed strategies, financials, and recent developments
Supply chain trends mapping the latest technological advancements


1 Executive Summary
2 Preface
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions
3 Market Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Application Analysis
3.7 Emerging Markets
4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 Global Nuclear Medicine Market, By Application
5.1 Introduction
5.2 Therapeutics
5.2.1 Bone Metastasis
5.2.2 Endocrine Tumors
5.2.3 Lymphoma
5.2.4 Thyroid
5.2.5 Nephrology
5.2.6 Cardiology
5.2.7 Neurology
5.2.8 Other Therapeutic Applications
5.3 Diagnostics
5.3.1 Positron Emission Tomography (PET)
5.3.1.1 Oncology
5.3.1.2 Neurology
5.3.1.3 Cardiology
5.3.1.4 Inflammation
5.3.1.5 Other PET Applications
5.3.2 Single Photon Emission Computed Tomography (SPECT)
5.3.2.1 Thyroid
5.3.2.2 Neurology
5.3.2.3 Lymphoma
5.3.2.4 Cardiology
5.3.2.5 Gastro Intestinal
5.3.2.6 Oncology
5.3.2.7 Nephrology
5.3.2.8 Inflammation
5.3.2.5 Other Diagnostic Applications
6 Global Nuclear Medicine Market, By Type
6.1 Introduction
6.2 Nuclear Medicine Therapeutic Isotopes
6.2.1 Alpha Emitters
6.2.1.1 Thorium-227 (Th-227)
6.2.1.2 Radium-224
6.2.1.3 Radium-223
6.2.1.4 Lead (Pb-212)/Bismuth (Bi-212)
6.2.1.5 Astatine (At-211)
6.2.1.6 Actinium (Ac-225)
6.2.1.7 Others
6.2.2 Brachytherapy
6.2.2.1 Palladium-103
6.2.2.2 Iridium-192
6.2.2.3 Iodine-125
6.2.2.4 Cesium-131
6.2.2.5 Others
6.2.3 Beta Emitters
6.2.3.1 Yttrium-90 (Y-90)
6.2.3.2 Samarium-153 (SM-153)
6.2.3.3 Rhenium-186 (Re-186)
6.2.3.4 Lutetium-177 (Lu-177)
6.2.3.5 Iodine-131 (I-131)
6.2.3.6 Erbium (Er-169)
6.2.3.7 Strontium (Sr-89)
6.2.3.8 Others
6.3 Nuclear Medicine/Radiopharmaceuticals Diagnostics
6.3.1 Positron Emission Tomography (PET) Radiopharmaceuticals
6.3.1.1 Rubidium-82 (RB-82)
6.3.1.2 Fluorodeoxyglucose (FDG)
6.3.1.3 Gallium (Ga-68)
6.3.1.4 Others
6.3.2 Single Photon Emission Computed Tomography (SPECT)
6.3.2.1 Technetium-99m (TC-99m)
6.3.2.2 Thallium-201 (TL-201)
6.3.2.3 Gallium-67 (GA-67)
6.3.2.4 Iodine (I-123)
6.3.2.5 Samarium
6.3.2.6 Yttrium
6.3.2.7 Rhenium
6.3.2.8 Others
7 Global Nuclear Medicine Market, By Procedural Volume
7.1 Introduction
7.2 Therapeutic
7.2.1 Alpha Emitters
7.2.2 Beta Emitters
7.2.3 Brachytherapy
7.3 Diagnostics
7.3.1 Single Photon Emission Computed Tomography (SPECT) Radiopharmaceuticals
7.3.2 Positron Emission Tomography (PET) Radiopharmaceuticals
8 Global Nuclear Medicine Market, By End User
8.1 Introduction
8.2 Academic Research Laboratories
8.3 Industries
8.4 Medical
8.4.1 Hospitals
8.4.2 Diagnostic Centers
9 Global Nuclear Medicine Market, By Stable Isotope
9.1 Introduction
9.2 Sulphur (S-32)
9.3 Oxygen (O-18)
9.4 Nitrogen (N-15)
9.5 Deuterium (D2)
9.6 Carbon (C-13)
9.7 Other Stable Isotopes
10 Global Nuclear Medicine Market, By Geography
10.1 North America
10.1.1 US
10.1.2 Canada
10.1.3 Mexico
10.2 Europe
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 UK
10.2.5 Spain
10.2.6 Rest of Europe
10.3 Asia Pacific
10.3.1 Japan
10.3.2 China
10.3.3 India
10.3.4 Australia
10.3.5 New Zealand
10.3.6 Rest of Asia Pacific
10.4 Rest of the World
10.4.1 Middle East
10.4.2 Brazil
10.4.3 Argentina
10.4.4 South Africa
10.4.5 Egypt
11 Key Developments
11.1 Agreements, Partnerships, Collaborations and Joint Ventures
11.2 Acquisitions & Mergers
11.3 New Product Launch
11.4 Expansions
11.5 Other Key Strategies
12 Company Profiling
12.1 Advanced Accelerator Applications S.A.
12.2 Ashby Gorman Baker Ltd,
12.3 Bayer Healthcare
12.4 Bracco Imaging S.P.A
12.5 Cardinal Health
12.6 Digirad
12.7 Eczcibasi-Monrol Nuclear Products
12.8 GE Healthcare
12.9 IBA Molecular Imaging
12.10 Lantheus Medical Imaging
12.11 Mallinckrodt PLC
12.12 Mediso Ltd.
12.13 Nordion, Inc.
12.14 Philips Healthcare
12.15 Siemens Healthcare
List of Tables
Table 1 Global Nuclear Medicine Market Outlook, By Region (2013-2022) ($MN)
Table 2 Global Nuclear Medicine Market Outlook, By Application (2013-2022) ($MN)
Table 3 Global Nuclear Medicine Market Outlook, By Therapeutics (2013-2022) ($MN)
Table 4 Global Nuclear Medicine Market Outlook, By Bone Metastasis (2013-2022) ($MN)
Table 5 Global Nuclear Medicine Market Outlook, By Endocrine Tumors (2013-2022) ($MN)
Table 6 Global Nuclear Medicine Market Outlook, By Lymphoma (2013-2022) ($MN)
Table 7 Global Nuclear Medicine Market Outlook, By Thyroid (2013-2022) ($MN)
Table 8 Global Nuclear Medicine Market Outlook, By Nephrology (2013-2022) ($MN)
Table 9 Global Nuclear Medicine Market Outlook, By Cardiology (2013-2022) ($MN)
Table 10 Global Nuclear Medicine Market Outlook, By Neurology (2013-2022) ($MN)
Table 11 Global Nuclear Medicine Market Outlook, By Other Therapeutic Applications (2013-2022) ($MN)
Table 12 Global Nuclear Medicine Market Outlook, By Diagnostics (2013-2022) ($MN)
Table 13 Global Nuclear Medicine Market Outlook, By Positron Emission Tomography (PET) (2013-2022) ($MN)
Table 14 Global Nuclear Medicine Market Outlook, By Single Photon Emission Computed Tomography (SPECT) (2013-2022) ($MN)
Table 15 Global Nuclear Medicine Market Outlook, By Type (2013-2022) ($MN)
Table 16 Global Nuclear Medicine Market Outlook, By Nuclear Medicine Therapeutic Isotopes (2013-2022) ($MN)
Table 17 Global Nuclear Medicine Market Outlook, By Alpha Emitters (2013-2022) ($MN)
Table 18 Global Nuclear Medicine Market Outlook, By Brachytherapy (2013-2022) ($MN)
Table 19 Global Nuclear Medicine Market Outlook, By Beta Emitters (2013-2022) ($MN)
Table 20 Global Nuclear Medicine Market Outlook, By Nuclear Medicine/Radiopharmaceuticals Diagnostics (2013-2022) ($MN)
Table 21 Global Nuclear Medicine Market Outlook, By Positron Emission Tomography (PET) Radiopharmaceuticals (2013-2022) ($MN)
Table 22 Global Nuclear Medicine Market Outlook, By Single Photon Emission Computed Tomography (SPECT) (2013-2022) ($MN)
Table 23 Global Nuclear Medicine Market Outlook, By Procedural Volume (2013-2022) ($MN)
Table 24 Global Nuclear Medicine Market Outlook, By Therapeutic (2013-2022) ($MN)
Table 25 Global Nuclear Medicine Market Outlook, By Alpha Emitters (2013-2022) ($MN)
Table 26 Global Nuclear Medicine Market Outlook, By Beta Emitters (2013-2022) ($MN)
Table 27 Global Nuclear Medicine Market Outlook, By Brachytherapy (2013-2022) ($MN)
Table 28 Global Nuclear Medicine Market Outlook, By Diagnostics (2013-2022) ($MN)
Table 29 Global Nuclear Medicine Market Outlook, By Single Photon Emission Computed Tomography (SPECT) Radiopharmaceuticals (2013-2022) ($MN)
Table 30 Global Nuclear Medicine Market Outlook, By Positron Emission Tomography (PET) Radiopharmaceuticals (2013-2022) ($MN)
Table 31 Global Nuclear Medicine Market Outlook, By End User (2013-2022) ($MN)
Table 32 Global Nuclear Medicine Market Outlook, By Academic Research Laboratories (2013-2022) ($MN)
Table 33 Global Nuclear Medicine Market Outlook, By Industries (2013-2022) ($MN)
Table 34 Global Nuclear Medicine Market Outlook, By Medical (2013-2022) ($MN)
Table 35 Global Nuclear Medicine Market Outlook, By Hospitals (2013-2022) ($MN)
Table 36 Global Nuclear Medicine Market Outlook, By Diagnostic Centers (2013-2022) ($MN)
Table 37 Global Nuclear Medicine Market Outlook, By Stable Isotope (2013-2022) ($MN)
Table 38 Global Nuclear Medicine Market Outlook, By Sulphur (S-32) (2013-2022) ($MN)
Table 39 Global Nuclear Medicine Market Outlook, By Oxygen (O-18) (2013-2022) ($MN)
Table 40 Global Nuclear Medicine Market Outlook, By Nitrogen (N-15) (2013-2022) ($MN)
Table 41 Global Nuclear Medicine Market Outlook, By Deuterium (D2) (2013-2022) ($MN)
Table 42 Global Nuclear Medicine Market Outlook, By Carbon (C-13) (2013-2022) ($MN)
Table 43 Global Nuclear Medicine Market Outlook, By Other stable isotopes (2013-2022) ($MN)
Table 44 North America Nuclear Medicine Market Outlook, By Country (2013-2022) ($MN)
Table 45 North America Nuclear Medicine Market Outlook, By Application (2013-2022) ($MN)
Table 46 North America Nuclear Medicine Market Outlook, By Therapeutics (2013-2022) ($MN)
Table 47 North America Nuclear Medicine Market Outlook, By Bone Metastasis (2013-2022) ($MN)
Table 48 North America Nuclear Medicine Market Outlook, By Endocrine Tumors (2013-2022) ($MN)
Table 49 North America Nuclear Medicine Market Outlook, By Lymphoma (2013-2022) ($MN)
Table 50 North America Nuclear Medicine Market Outlook, By Thyroid (2013-2022) ($MN)
Table 51 North America Nuclear Medicine Market Outlook, By Nephrology (2013-2022) ($MN)
Table 52 North America Nuclear Medicine Market Outlook, By Cardiology (2013-2022) ($MN)
Table 53 North America Nuclear Medicine Market Outlook, By Neurology (2013-2022) ($MN)
Table 54 North America Nuclear Medicine Market Outlook, By Other Therapeutic Applications (2013-2022) ($MN)
Table 55 North America Nuclear Medicine Market Outlook, By Diagnostics (2013-2022) ($MN)
Table 56 North America Nuclear Medicine Market Outlook, By Positron Emission Tomography (PET) (2013-2022) ($MN)
Table 57 North America Nuclear Medicine Market Outlook, By Single Photon Emission Computed Tomography (SPECT) (2013-2022) ($MN)
Table 58 North America Nuclear Medicine Market Outlook, By Type (2013-2022) ($MN)
Table 59 North America Nuclear Medicine Market Outlook, By Nuclear Medicine Therapeutic Isotopes (2013-2022) ($MN)
Table 60 North America Nuclear Medicine Market Outlook, By Alpha Emitters (2013-2022) ($MN)
Table 61 North America Nuclear Medicine Market Outlook, By Brachytherapy (2013-2022) ($MN)
Table 62 North America Nuclear Medicine Market Outlook, By Beta Emitters (2013-2022) ($MN)
Table 63 North America Nuclear Medicine Market Outlook, By Nuclear Medicine/Radiopharmaceuticals Diagnostics (2013-2022) ($MN)
Table 64 North America Nuclear Medicine Market Outlook, By Positron Emission Tomography (PET) Radiopharmaceuticals (2013-2022) ($MN)
Table 65 North America Nuclear Medicine Market Outlook, By Single Photon Emission Computed Tomography (SPECT) (2013-2022) ($MN)
Table 66 North America Nuclear Medicine Market Outlook, By Procedural Volume (2013-2022) ($MN)
Table 67 North America Nuclear Medicine Market Outlook, By Therapeutic (2013-2022) ($MN)
Table 68 North America Nuclear Medicine Market Outlook, By Alpha Emitters (2013-2022) ($MN)
Table 69 North America Nuclear Medicine Market Outlook, By Beta Emitters (2013-2022) ($MN)
Table 70 North America Nuclear Medicine Market Outlook, By Brachytherapy (2013-2022) ($MN)
Table 71 North America Nuclear Medicine Market Outlook, By Diagnostics (2013-2022) ($MN)
Table 72 North America Nuclear Medicine Market Outlook, By Single Photon Emission Computed Tomography (SPECT) Radiopharmaceuticals (2013-2022) ($MN)
Table 73 North America Nuclear Medicine Market Outlook, By Positron Emission Tomography (PET) Radiopharmaceuticals (2013-2022) ($MN)
Table 74 North America Nuclear Medicine Market Outlook, By End User (2013-2022) ($MN)
Table 75 North America Nuclear Medicine Market Outlook, By Academic Research Laboratories (2013-2022) ($MN)
Table 76 North America Nuclear Medicine Market Outlook, By Industries (2013-2022) ($MN)
Table 77 North America Nuclear Medicine Market Outlook, By Medical (2013-2022) ($MN)
Table 78 North America Nuclear Medicine Market Outlook, By Hospitals (2013-2022) ($MN)
Table 79 North America Nuclear Medicine Market Outlook, By Diagnostic Centers (2013-2022) ($MN)
Table 80 North America Nuclear Medicine Market Outlook, By Stable Isotope (2013-2022) ($MN)
Table 81 North America Nuclear Medicine Market Outlook, By Sulphur (S-32) (2013-2022) ($MN)
Table 82 North America Nuclear Medicine Market Outlook, By Oxygen (O-18) (2013-2022) ($MN)
Table 83 North America Nuclear Medicine Market Outlook, By Nitrogen (N-15) (2013-2022) ($MN)
Table 84 North America Nuclear Medicine Market Outlook, By Deuterium (D2) (2013-2022) ($MN)
Table 85 North America Nuclear Medicine Market Outlook, By Carbon (C-13) (2013-2022) ($MN)
Table 86 North America Nuclear Medicine Market Outlook, By Other stable isotopes (2013-2022) ($MN)
Table 87 Europe Nuclear Medicine Market Outlook, By Country (2013-2022) ($MN)
Table 88 Europe Nuclear Medicine Market Outlook, By Application (2013-2022) ($MN)
Table 89 Europe Nuclear Medicine Market Outlook, By Therapeutics (2013-2022) ($MN)
Table 90 Europe Nuclear Medicine Market Outlook, By Bone Metastasis (2013-2022) ($MN)
Table 91 Europe Nuclear Medicine Market Outlook, By Endocrine Tumors (2013-2022) ($MN)
Table 92 Europe Nuclear Medicine Market Outlook, By Lymphoma (2013-2022) ($MN)
Table 93 Europe Nuclear Medicine Market Outlook, By Thyroid (2013-2022) ($MN)
Table 94 Europe Nuclear Medicine Market Outlook, By Nephrology (2013-2022) ($MN)
Table 95 Europe Nuclear Medicine Market Outlook, By Cardiology (2013-2022) ($MN)
Table 96 Europe Nuclear Medicine Market Outlook, By Neurology (2013-2022) ($MN)
Table 97 Europe Nuclear Medicine Market Outlook, By Other Therapeutic Applications (2013-2022) ($MN)
Table 98 Europe Nuclear Medicine Market Outlook, By Diagnostics (2013-2022) ($MN)
Table 99 Europe Nuclear Medicine Market Outlook, By Positron Emission Tomography (PET) (2013-2022) ($MN)
Table 100 Europe Nuclear Medicine Market Outlook, By Single Photon Emission Computed Tomography (SPECT) (2013-2022) ($MN)
Table 101 Europe Nuclear Medicine Market Outlook, By Type (2013-2022) ($MN)
Table 102 Europe Nuclear Medicine Market Outlook, By Nuclear Medicine Therapeutic Isotopes (2013-2022) ($MN)
Table 103 Europe Nuclear Medicine Market Outlook, By Alpha Emitters (2013-2022) ($MN)
Table 104 Europe Nuclear Medicine Market Outlook, By Brachytherapy (2013-2022) ($MN)
Table 105 Europe Nuclear Medicine Market Outlook, By Beta Emitters (2013-2022) ($MN)
Table 106 Europe Nuclear Medicine Market Outlook, By Nuclear Medicine/Radiopharmaceuticals Diagnostics (2013-2022) ($MN)
Table 107 Europe Nuclear Medicine Market Outlook, By Positron Emission Tomography (PET) Radiopharmaceuticals (2013-2022) ($MN)
Table 108 Europe Nuclear Medicine Market Outlook, By Single Photon Emission Computed Tomography (SPECT) (2013-2022) ($MN)
Table 109 Europe Nuclear Medicine Market Outlook, By Procedural Volume (2013-2022) ($MN)
Table 110 Europe Nuclear Medicine Market Outlook, By Therapeutic (2013-2022) ($MN)
Table 111 Europe Nuclear Medicine Market Outlook, By Alpha Emitters (2013-2022) ($MN)
Table 112 Europe Nuclear Medicine Market Outlook, By Beta Emitters (2013-2022) ($MN)
Table 113 Europe Nuclear Medicine Market Outlook, By Brachytherapy (2013-2022) ($MN)
Table 114 Europe Nuclear Medicine Market Outlook, By Diagnostics (2013-2022) ($MN)
Table 115 Europe Nuclear Medicine Market Outlook, By Single Photon Emission Computed Tomography (SPECT) Radiopharmaceuticals (2013-2022) ($MN)
Table 116 Europe Nuclear Medicine Market Outlook, By Positron Emission Tomography (PET) Radiopharmaceuticals (2013-2022) ($MN)
Table 117 Europe Nuclear Medicine Market Outlook, By End User (2013-2022) ($MN)
Table 118 Europe Nuclear Medicine Market Outlook, By Academic Research Laboratories (2013-2022) ($MN)
Table 119 Europe Nuclear Medicine Market Outlook, By Industries (2013-2022) ($MN)
Table 120 Europe Nuclear Medicine Market Outlook, By Medical (2013-2022) ($MN)
Table 121 Europe Nuclear Medicine Market Outlook, By Hospitals (2013-2022) ($MN)
Table 122 Europe Nuclear Medicine Market Outlook, By Diagnostic Centers (2013-2022) ($MN)
Table 123 Europe Nuclear Medicine Market Outlook, By Stable Isotope (2013-2022) ($MN)
Table 124 Europe Nuclear Medicine Market Outlook, By Sulphur (S-32) (2013-2022) ($MN)
Table 125 Europe Nuclear Medicine Market Outlook, By Oxygen (O-18) (2013-2022) ($MN)
Table 126 Europe Nuclear Medicine Market Outlook, By Nitrogen (N-15) (2013-2022) ($MN)
Table 127 Europe Nuclear Medicine Market Outlook, By Deuterium (D2) (2013-2022) ($MN)
Table 128 Europe Nuclear Medicine Market Outlook, By Carbon (C-13) (2013-2022) ($MN)
Table 129 Europe Nuclear Medicine Market Outlook, By Other stable isotopes (2013-2022) ($MN)
Table 130 Asia Pacific Nuclear Medicine Market Outlook, By Country (2013-2022) ($MN)
Table 131 Asia Pacific Nuclear Medicine Market Outlook, By Application (2013-2022) ($MN)
Table 132 Asia Pacific Nuclear Medicine Market Outlook, By Therapeutics (2013-2022) ($MN)
Table 133 Asia Pacific Nuclear Medicine Market Outlook, By Bone Metastasis (2013-2022) ($MN)
Table 134 Asia Pacific Nuclear Medicine Market Outlook, By Endocrine Tumors (2013-2022) ($MN)
Table 135 Asia Pacific Nuclear Medicine Market Outlook, By Lymphoma (2013-2022) ($MN)
Table 136 Asia Pacific Nuclear Medicine Market Outlook, By Thyroid (2013-2022) ($MN)
Table 137 Asia Pacific Nuclear Medicine Market Outlook, By Nephrology (2013-2022) ($MN)
Table 138 Asia Pacific Nuclear Medicine Market Outlook, By Cardiology (2013-2022) ($MN)
Table 139 Asia Pacific Nuclear Medicine Market Outlook, By Neurology (2013-2022) ($MN)
Table 140 Asia Pacific Nuclear Medicine Market Outlook, By Other Therapeutic Applications (2013-2022) ($MN)
Table 141 Asia Pacific Nuclear Medicine Market Outlook, By Diagnostics (2013-2022) ($MN)
Table 142 Asia Pacific Nuclear Medicine Market Outlook, By Positron Emission Tomography (PET) (2013-2022) ($MN)
Table 143 Asia Pacific Nuclear Medicine Market Outlook, By Single Photon Emission Computed Tomography (SPECT) (2013-2022) ($MN)
Table 144 Asia Pacific Nuclear Medicine Market Outlook, By Type (2013-2022) ($MN)
Table 145 Asia Pacific Nuclear Medicine Market Outlook, By Nuclear Medicine Therapeutic Isotopes (2013-2022) ($MN)
Table 146 Asia Pacific Nuclear Medicine Market Outlook, By Alpha Emitters (2013-2022) ($MN)
Table 147 Asia Pacific Nuclear Medicine Market Outlook, By Brachytherapy (2013-2022) ($MN)
Table 148 Asia Pacific Nuclear Medicine Market Outlook, By Beta Emitters (2013-2022) ($MN)
Table 149 Asia Pacific Nuclear Medicine Market Outlook, By Nuclear Medicine/Radiopharmaceuticals Diagnostics (2013-2022) ($MN)
Table 150 Asia Pacific Nuclear Medicine Market Outlook, By Positron Emission Tomography (PET) Radiopharmaceuticals (2013-2022) ($MN)
Table 151 Asia Pacific Nuclear Medicine Market Outlook, By Single Photon Emission Computed Tomography (SPECT) (2013-2022) ($MN)
Table 152 Asia Pacific Nuclear Medicine Market Outlook, By Procedural Volume (2013-2022) ($MN)
Table 153 Asia Pacific Nuclear Medicine Market Outlook, By Therapeutic (2013-2022) ($MN)
Table 154 Asia Pacific Nuclear Medicine Market Outlook, By Alpha Emitters (2013-2022) ($MN)
Table 155 Asia Pacific Nuclear Medicine Market Outlook, By Beta Emitters (2013-2022) ($MN)
Table 156 Asia Pacific Nuclear Medicine Market Outlook, By Brachytherapy (2013-2022) ($MN)
Table 157 Asia Pacific Nuclear Medicine Market Outlook, By Diagnostics (2013-2022) ($MN)
Table 158 Asia Pacific Nuclear Medicine Market Outlook, By Single Photon Emission Computed Tomography (SPECT) Radiopharmaceuticals (2013-2022) ($MN)
Table 159 Asia Pacific Nuclear Medicine Market Outlook, By Positron Emission Tomography (PET) Radiopharmaceuticals (2013-2022) ($MN)
Table 160 Asia Pacific Nuclear Medicine Market Outlook, By End User (2013-2022) ($MN)
Table 161 Asia Pacific Nuclear Medicine Market Outlook, By Academic Research Laboratories (2013-2022) ($MN)
Table 162 Asia Pacific Nuclear Medicine Market Outlook, By Industries (2013-2022) ($MN)
Table 163 Asia Pacific Nuclear Medicine Market Outlook, By Medical (2013-2022) ($MN)
Table 164 Asia Pacific Nuclear Medicine Market Outlook, By Hospitals (2013-2022) ($MN)
Table 165 Asia Pacific Nuclear Medicine Market Outlook, By Diagnostic Centers (2013-2022) ($MN)
Table 166 Asia Pacific Nuclear Medicine Market Outlook, By Stable Isotope (2013-2022) ($MN)
Table 167 Asia Pacific Nuclear Medicine Market Outlook, By Sulphur (S-32) (2013-2022) ($MN)
Table 168 Asia Pacific Nuclear Medicine Market Outlook, By Oxygen (O-18) (2013-2022) ($MN)
Table 169 Asia Pacific Nuclear Medicine Market Outlook, By Nitrogen (N-15) (2013-2022) ($MN)
Table 170 Asia Pacific Nuclear Medicine Market Outlook, By Deuterium (D2) (2013-2022) ($MN)
Table 171 Asia Pacific Nuclear Medicine Market Outlook, By Carbon (C-13) (2013-2022) ($MN)
Table 172 Asia Pacific Nuclear Medicine Market Outlook, By Other stable isotopes (2013-2022) ($MN)
Table 173 RoW Nuclear Medicine Market Outlook, By Country (2013-2022) ($MN)
Table 174 RoW Nuclear Medicine Market Outlook, By Application (2013-2022) ($MN)
Table 175 RoW Nuclear Medicine Market Outlook, By Therapeutics (2013-2022) ($MN)
Table 176 RoW Nuclear Medicine Market Outlook, By Bone Metastasis (2013-2022) ($MN)
Table 177 RoW Nuclear Medicine Market Outlook, By Endocrine Tumors (2013-2022) ($MN)
Table 178 RoW Nuclear Medicine Market Outlook, By Lymphoma (2013-2022) ($MN)
Table 179 RoW Nuclear Medicine Market Outlook, By Thyroid (2013-2022) ($MN)
Table 180 RoW Nuclear Medicine Market Outlook, By Nephrology (2013-2022) ($MN)
Table 181 RoW Nuclear Medicine Market Outlook, By Cardiology (2013-2022) ($MN)
Table 182 RoW Nuclear Medicine Market Outlook, By Neurology (2013-2022) ($MN)
Table 183 RoW Nuclear Medicine Market Outlook, By Other Therapeutic Applications (2013-2022) ($MN)
Table 184 RoW Nuclear Medicine Market Outlook, By Diagnostics (2013-2022) ($MN)
Table 185 RoW Nuclear Medicine Market Outlook, By Positron Emission Tomography (PET) (2013-2022) ($MN)
Table 186 RoW Nuclear Medicine Market Outlook, By Single Photon Emission Computed Tomography (SPECT) (2013-2022) ($MN)
Table 187 RoW Nuclear Medicine Market Outlook, By Type (2013-2022) ($MN)
Table 188 RoW Nuclear Medicine Market Outlook, By Nuclear Medicine Therapeutic Isotopes (2013-2022) ($MN)
Table 189 RoW Nuclear Medicine Market Outlook, By Alpha Emitters (2013-2022) ($MN)
Table 190 RoW Nuclear Medicine Market Outlook, By Brachytherapy (2013-2022) ($MN)
Table 191 RoW Nuclear Medicine Market Outlook, By Beta Emitters (2013-2022) ($MN)
Table 192 RoW Nuclear Medicine Market Outlook, By Nuclear Medicine/Radiopharmaceuticals Diagnostics (2013-2022) ($MN)
Table 193 RoW Nuclear Medicine Market Outlook, By Positron Emission Tomography (PET) Radiopharmaceuticals (2013-2022) ($MN)
Table 194 RoW Nuclear Medicine Market Outlook, By Single Photon Emission Computed Tomography (SPECT) (2013-2022) ($MN)
Table 195 RoW Nuclear Medicine Market Outlook, By Procedural Volume (2013-2022) ($MN)
Table 196 RoW Nuclear Medicine Market Outlook, By Therapeutic (2013-2022) ($MN)
Table 197 RoW Nuclear Medicine Market Outlook, By Alpha Emitters (2013-2022) ($MN)
Table 198 RoW Nuclear Medicine Market Outlook, By Beta Emitters (2013-2022) ($MN)
Table 199 RoW Nuclear Medicine Market Outlook, By Brachytherapy (2013-2022) ($MN)
Table 200 RoW Nuclear Medicine Market Outlook, By Diagnostics (2013-2022) ($MN)
Table 201 RoW Nuclear Medicine Market Outlook, By Single Photon Emission Computed Tomography (SPECT) Radiopharmaceuticals (2013-2022) ($MN)
Table 202 RoW Nuclear Medicine Market Outlook, By Positron Emission Tomography (PET) Radiopharmaceuticals (2013-2022) ($MN)
Table 203 RoW Nuclear Medicine Market Outlook, By End User (2013-2022) ($MN)
Table 204 RoW Nuclear Medicine Market Outlook, By Academic Research Laboratories (2013-2022) ($MN)
Table 205 RoW Nuclear Medicine Market Outlook, By Industries (2013-2022) ($MN)
Table 206 RoW Nuclear Medicine Market Outlook, By Medical (2013-2022) ($MN)
Table 207 RoW Nuclear Medicine Market Outlook, By Hospitals (2013-2022) ($MN)
Table 208 RoW Nuclear Medicine Market Outlook, By Diagnostic Centers (2013-2022) ($MN)
Table 209 RoW Nuclear Medicine Market Outlook, By Stable Isotope (2013-2022) ($MN)
Table 210 RoW Nuclear Medicine Market Outlook, By Sulphur (S-32) (2013-2022) ($MN)
Table 211 RoW Nuclear Medicine Market Outlook, By Oxygen (O-18) (2013-2022) ($MN)
Table 212 RoW Nuclear Medicine Market Outlook, By Nitrogen (N-15) (2013-2022) ($MN)
Table 213 RoW Nuclear Medicine Market Outlook, By Deuterium (D2) (2013-2022) ($MN)
Table 214 RoW Nuclear Medicine Market Outlook, By Carbon (C-13) (2013-2022) ($MN)
Table 215 RoW Nuclear Medicine Market Outlook, By Other stable isotopes (2013-2022) ($MN)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report